nature portfolio

Corresponding author(s):	Li Liao
Last updated by author(s):	Feb 8, 2025

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

~					
<.	トコ	ıŤ١	ict	Γ	C

For	all statistical ar	alyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.			
n/a	Confirmed				
	\square The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement				
	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly				
	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.				
\boxtimes	A description of all covariates tested				
\boxtimes	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons				
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)				
	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted Give <i>P</i> values as exact values whenever suitable.				
\boxtimes	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings				
\boxtimes	For hierar	chical and complex designs, identification of the appropriate level for tests and full reporting of outcomes			
\boxtimes	\square Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated				
Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.					
Software and code					
Poli	cy information	about <u>availability of computer code</u>			
D	ata collection	Does not apply. All softwares are publically available and described in the manuscript.			
D	ata analysis	Does not apply. All softwares are publically available and described in the manuscript.			
		g custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and			

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

The raw RIP-seq data reported in this study has been uploaded in NCBI's Sequence Read Archive (SRA, accession numbers: SRR29791929 to SRR29791952) under the BioProject accession number: PRJNA1134920.

Research involving human participants, their data, or biological material

Policy information about sto and sexual orientation and j	udies with <u>human participants or human data</u> . See also policy information about <u>sex, gender (identity/presentation),</u> race, ethnicity and racism.		
Reporting on sex and gen	der Does not apply.		
Reporting on race, ethnic other socially relevant groupings	Does not apply.		
Population characteristics	Does not apply.		
Recruitment	Does not apply.		
Ethics oversight	Does not apply.		
Note that full information on th	ne approval of the study protocol must also be provided in the manuscript.		
Field-specific	reporting		
Please select the one below	that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.		
Life sciences	Behavioural & social sciences		
For a reference copy of the docume	ent with all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>		
	volutionary & environmental sciences study design these points even when the disclosure is negative.		
Study description	We investigated the targets of the CsrA protein using RIP-Seq . Furthermore, we analyzed the dynamics of the CsrA targetome by examining the differences in the CsrA protein targets among these various samples. RIP-Seq involves four strains (WT, Δ Pf1, Δ Pf12 and Δ Pf123) with three biological replicates set for each strain.		
Research sample	Pseudoalteromonas fuliginea BSW20308 is a cold-adapted bacterium isolated from the Chukchi Sea in the Arctic. We constructed Δ Pf1, Δ Pf12, Δ Pf123 mutants based on P. fuliginea BSW20308.		
Sampling strategy	Does not apply.		
Data collection	The collected data are checked and recorded by authors. Data were collected from experimental results.		
Timing and spatial scale	It was not necessary for this study.		
Data exclusions	Quality control was conducted on the raw sequence data as described in the manuscript.		
Reproducibility	n growth measurement, we established nine biological replicates for each strain. For the RIP-Seq experiment, we selected three biological replicates per strain to ensure the reliability of the experimental results. The experiments conducted in this study were repeated more than twice.		
Randomization	Randomization was not necessary for this study.		
Blinding	Blinding was not necessary for this study.		
Did the study involve field	work? Yes No		

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experime	ental systems	Methods
n/a Involved in the study		n/a Involved in the study
Antibodies		ChIP-seq
Eukaryotic cell lines	1	Flow cytometry
Palaeontology and a	archaeology	MRI-based neuroimaging
Animals and other of	organisms	
Clinical data		
Dual use research o	f concern	
Plants		
Seed stocks	Does not apply.	
Novel plant genotypes	Does not apply.	
Authentication	Does not apply.	